SUDA Pharmaceuticals

SUDA Pharmaceuticals Ltd (SUDA), based in Australia and the US, is a world leader in reformulating and delivering medication through the oral mucosa.

Patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream.

SUDA can increase the bioavailability of administered medications, which means it increases the amount of the drug absorbed by the body so is able to increase the effect of that drug.

SUDA has increased bioavailability up to 95%. This is a major step forward in the evolution of drug delivery technology.

Latest Media Releases

SUDA Signs Additional Licence With Mitsubishi Tanabe

23/03/2020 09:44:00

SUDA Pharmaceuticals Ltd (ASX: SUD), a leader inoro-mucosal drug delivery, today announces that it has entered into an exclusive licenseagreement with Mitsubishi Tanabe Pharma Korea Ltd (MTPK), a wh…

Half Yearly Report and Accounts

26/02/2020 18:01:00

  Key achievements: 1. SUDA secured three new agreements: Cann Pharma Australia for a novel oral spray of cannabinoid derivatives; and two feasibility studies with Laboratorios Ordesa, S.L. and…

SUDA Pharmaceuticals - Appendix 4C - quarterly

31/01/2020 12:29:00

SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the second quarter of FY 2020. During the quarter, the Compa…

Latest News